As proven by the success of the Spikevax COVID-19 vaccine, Moderna aims to build on this achievement by expanding into applications for influenza, cancer, and rare diseases. The value of your investments can go down as well as up and you may get back less than you put in. Tax treatment depends on your individual circumstances and may be subject to future change.
Madison Mills examines the trending headlines Wall Street investors need to know on today’s Market Minute. Moderna (MRNA) shares pop after a German court ruled that Pfizer (PFE) and BioNTech (BNTX) violated Moderna’s COVID vaccine patent. Alibaba (BABA) and Tencent (TCEHY) shares are trading higher after Bernstein analysts boosted their price targets for the Chinese tech stocks. BlackRock (BLK) stock is in focus as the company takes the lead on the $22.8 billion deal to control two key Panama Canal ports.
Moderna: Fresh Sell-Off On Cost Cutting Initiatives, Short-Term Outlook Troubling
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm’s mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 40 mRNA development candidates in clinical development as of September 2024. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases. Moderna is recognized as a pioneer in messenger RNA (mRNA) technology, seen as a potential game changer in medicine. This technology uses the body’s cellular machinery to fight diseases by directing cells to produce proteins that trigger a specific immune response or address a particular health issue.
Price Volatility
The company has experienced rapid growth due to its innovative mRNA technologies, especially as the U.S. authorized the COVID-19 vaccine developed by Moderna Inc. for human use in December 2020. Adding to Moderna’s woes, its highly anticipated respiratory syncytial virus (RSV) vaccine, known as mRESVI and approved by the Food and Drug Administration (FDA) in 2024 as the company’s only other commercialized product beyond Spikevax, has faced a sluggish rollout. Global uptake has been slow, with low demand for its current indication to protect adults aged 60 years and older from lower respiratory tract disease caused by RSV infection, generating just $25 million in sales last year. For the period ending 30 September, the group reported earnings per share of $7.70. But the company now expects to sell fewer vaccines throughout the rest of 2021. It was initially projecting total vaccine sales for the year of $20bn.
Moderna is a leader in the creation of the field of mRNA medicine. Through the advancement of mRNA technology, Moderna is reimagining how medicines are made and transforming how we treat and prevent disease for everyone. By working at the intersection of science, technology and health for more than a decade, the company has developed medicines at unprecedented forex trading psychology speed and efficiency, including one of the earliest and most effective COVID-19 vaccines. Founded in 1993 by brothers Tom and David Gardner, The Motley Fool helps millions of people attain financial freedom through our website, podcasts, books, newspaper column, radio show and premium investing services.
Performance Overview: MRNA
This includes vaccines for norovirus and cytomegalovirus, with data readouts expected this year. Perhaps the most promising is mRNA-4157, a personalized therapeutic cancer vaccine in phase 3 trials for treating melanoma, along with renal cell carcinoma and bladder cancer in phase 2 studies. Its potential to transform oncology How to invest in 5g with a tailored immune approach could position Moderna as a major player in cancer therapeutics.
Part of these declines can be traced back to the company’s poor third-quarter results. Rupert Hargreaves explains why he thinks the Moderna share price is attractively priced after the company’s recent declines. Rupert Hargreaves explains why he thinks the Moderna share price is attractively priced after the company’s recent declines.
My 3 best stocks to buy in 2023
The top executives of Moderna, Akamai, and FMC just bought stock on the open market. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. Moderna (MRNA) raised $499 million in an initial public offering (IPO) on Friday, December 7th 2018. The company issued 21,700,000 shares at a price of $22.00-$24.00 per share.
Moderna (MRNA) Presents at Barclays 27th Annual Global Healthcare Conference (Transcript)
Moderna’s mRNA platform has enabled the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases. With a unique culture and a global team driven by the Moderna values and mindsets to responsibly change the future of human health, Moderna strives to deliver the greatest possible impact to people through mRNA medicines. For more information about Moderna, please visit modernatx.com and connect with us on X (formerly Twitter), Facebook, Instagram, YouTube and LinkedIn.
Researchers have been trying to develop a vaccine for this virus for more than five decades. It looks as if Moderna stands a chance at being able to crack the code with its mRNA technology. Analysts estimate the potential market for such a treatment could be worth as much as $5bn a year for the company. Britain’s health regulator said on Friday it has approved Moderna’s vaccine to protect patients aged 60 and over against lower respiratory tract disease caused by the respiratory syncytial virus (RSV)… As the company continues to advance its technologies and expand its strategic alliances, Moderna Inc. is proving to be a reliable source of transformative medicines to combat viruses and other diseases.
- Moderna (MRNA) shares pop after a German court ruled that Pfizer (PFE) and BioNTech (BNTX) violated Moderna’s COVID vaccine patent.
- Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally.
- Despite efforts to control costs and improve financial efficiency, Moderna reported a net loss of $3.6 billion last year, or a loss of $9.28 per share, only modestly improved from a loss of $12.33 in 2023.
- Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.
- You must click the activation link in order to complete your subscription.
Analyst Confident In Moderna’s Cancer Vaccine But Highlights Other Challenges
This virus infects the majority of people at some point during their lifetime. Infections are often benign, but it poses a significant risk to pregnant mothers and recipients of donated organs. You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more.
For 2025, Moderna forecasts total company sales of between $1.5 billion and $2.5 billion, reflecting its struggle to find a new blockbuster drug. The group also has a range of other treatments in its development pipeline, although it could be some time before these reach the market. In October, Moderna started recruiting patients for a Phase 3 trial of its mRNA Cytomegalovirus (CMV) Vaccine.
Explore Moderna stock price, quotes, charts and forecasts with Benzinga. To opt-in for investor email alerts, please enter your email address in the field below and select at what is bitcoin cash bitcoin vs bitcoin cash and price for february least one alert option. After submitting your request, you will receive an activation email to the requested email address. You must click the activation link in order to complete your subscription. Discover which analysts rank highest on predicting the price target of MRNA. Discover which analysts rank highest for MRNA overall weighted by direction, price target, and price movement.
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
- It’s been nearly five years since Moderna (MRNA -2.49%) emerged as a biotech industry disruptor, with its COVID-19 vaccine playing a landmark role in tackling the global pandemic in late 2020.
- The good news is that Moderna’s balance sheet, with $9.5 billion in cash and investments at the end of 2024, provides the financial flexibility to pursue these ambitious objectives.
- Explore Moderna stock price, quotes, charts and forecasts with Benzinga.
- Moderna Inc. is actively working to develop a range of pharmaceutical solutions and vaccines and to increase its strategic alliances.
Please bear with us as we address this and restore your personalized lists. Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data.
